Atlanta, USA / Ahmedabad, India, May 21, 2025 – Senores Pharmaceuticals Limited (“SPL”), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (“SPI”), has signed agreement today to acquire the USFDA-approved Abbreviated New Drug Application (“ANDA”) for Enalapril Maleate Tablets 2.5mg, 5mg, 10mg and 20mg from Wockhardt Limited (“Wockhardt”).
Enalapril is indicated as a treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction. The market size of Enalapril Tablet in the USA was ~USD 28.60 Mn (MAT December 2024)1 as per IQVIA and ~USD 109.24 Mn (MAT March 2025)2 as per the specialty data aggregator Symphony.
